{"id":"60329985751-43","name":"Shire","registrationDate":"2011-04-28T18:17:56.779+02:00","category":2,"subCategory":3,"legal":"Limited company","web":"http://www.shire.com/shireplc/en/home","country":"Switzerland","headAddress":"Takeda","headCity":"Zurich","headPostCode":"8152","headPhone":"(41)4 45 55 10 00","boss":"Giles Platford","bossTitle":"Mr","bossPosition":"President EUCAN Business Unit","membersCount":6,"membersFTE":"2.0","membership":"European Association of Bioindustries (EuropaBio)&#xd;\nEuropean Confederation of Pharmaceutical Entrepreneurs (EUCOPE) &#xd;\nEuropean Federation of Pharmaceutical Industries and Associations (EFPIA)&#xd;\nPlasma Protein Therapeutics Association (PPTA)&#xd;\n&#xd;\nAmerican Chamber of Commerce to the European Union (AmCham EU)&#xd;\nBritish Chamber of Commerce in Belgium&#xd;\nEuropean Policy Centre (EPC)&#xd;\nFriends of Europe","memberOrga":"","goal":"Shire is the leading global biotechnology company focused on serving people affected by rare diseases and highly specialized conditions. These diseases are often misunderstood, under-diagnosed, and potentially life-threatening.&#xd;<br />&#xd;<br />We are dedicated to expanding, building and sustaining leadership across our key therapeutic areas through our extensive portfolio of products, innovative pipeline and collaborative approach to working with diverse partners around the globe. We strive to earn and keep the trust of our patients, their families and physicians, and all others who support and advance their care.","acronym":"Shire","interests":"Business and Industry, Competition, Consumers, Digital economy and society, Economy, finance and the euro, Education and training, Employment and Social Affairs, Energy, Environment, Institutional affairs, Public Health, Research and innovation, Single market, Taxation, Trade, Youth","euInitiatives":"Note that on 8 January 2019 Takeda completed its acquisition of Shire. Takeda will provide a consolidated update on the combined company as part of its planned annual update, due by 13 September 2019.&#xd;<br />&#xd;<br />Shire follows all initiatives, policies, and legislation related to the biopharmaceutical sector and patient access to innovative medicines. These include:&#xd;<br />&#xd;<br />European Commission's annual work programme&#xd;<br />European Medicines Agency&#xd;<br />Healthcare policies&#xd;<br />Health Technology Assessment&#xd;<br />Innovative Medicines Initiative&#xd;<br />Intellectual Property&#xd;<br />Patient access to innovative medicines&#xd;<br />Patient safety&#xd;<br />Personalised medicines&#xd;<br />Pharmaceutical legislation&#xd;<br />Pharmaceutical sector policies&#xd;<br />Rare disease policies&#xd;<br />Research &amp; Development","lastUp":"2019-04-17T17:55:41.266+02:00","customers":"","costAbsolu":"","costRange":"600000-699999","turnoverAbsolu":0,"turnoverRange":""}